Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04608318
Recruitment Status : Recruiting
First Posted : October 29, 2020
Last Update Posted : January 24, 2022
Sponsor:
Collaborators:
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)
Nordic CLL Study Group (NCLLSG)
Swiss Group for Clinical Cancer Research (SAKK)
Cancer Trials Ireland
Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA)
Grupo Español de Leucemia Linfocítica Crónica (GELLC)
The Israeli CLL Study Group (ICLLSG)
Information provided by (Responsible Party):
German CLL Study Group

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2027
Estimated Study Completion Date : March 2027